S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)
Free Trial
OTCMKTS:EVTCY

Evotec (EVTCY) Stock Price, News & Analysis

→ 2024's Must-Have Guide: Master Crypto Investment Today (From Darwin) (Ad)
Free EVTCY Stock Alerts
$7.15
-0.09 (-1.24%)
(As of 04/18/2024 ET)
Compare
Today's Range
$6.98
▼
$7.19
50-Day Range
$6.89
▼
$7.87
52-Week Range
$14.22
▼
$26.57
Volume
27,408 shs
Average Volume
2,407 shs
Market Capitalization
$2.36 billion
P/E Ratio
17.44
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartFinancialsHeadlinesSEC Filings
EVTCY stock logo

About Evotec Stock (OTCMKTS:EVTCY)

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

EVTCY Stock Price History

EVTCY Stock News Headlines

March 6, 2024 | finanznachrichten.de
Evotec SE: Evotec And Claris Ventures Streamline Access to Accelerate Programmes from Claris's Portfolio Companies into The Clinic
January 10, 2024 | finanznachrichten.de
Evotec SE: Evotec and Crohn's & Colitis Foundation Enter Agreement to Advance Drug Discovery for Novel IBD Therapies
April 19, 2024 | Tips4Traders (Ad)
Uncover this 2024 Hidden Gem
Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.
January 4, 2024 | markets.businessinsider.com
Evotec, Owkin Anounce A.I.-Powered Collaboration In Oncology, Immunology, And Inflammation
November 12, 2023 | finance.yahoo.com
Evotec SE (NASDAQ:EVO) Q3 2023 Earnings Call Transcript
November 8, 2023 | markets.businessinsider.com
EQS-News: Evotec SE reports results for the first nine months 2023 and provides corporate update
October 5, 2023 | finance.yahoo.com
65LAB Launches in Partnership with Evotec SE and Backed by Leading Global Investors to Advance Drug Discovery and New Company Creation in Singapore
September 27, 2023 | finance.yahoo.com
Evotec SE: Launch of Partnering Agreement to Strengthen Biotech Innovators in Shared R&D Economy
April 19, 2024 | Tips4Traders (Ad)
Uncover this 2024 Hidden Gem
Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.
September 21, 2023 | finance.yahoo.com
Evotec SE (EVO) Stock Historical Prices & Data - Yahoo Finance
May 30, 2023 | finance.yahoo.com
Is There Now An Opportunity In Evotec SE (ETR:EVT)?
May 14, 2023 | finance.yahoo.com
Evotec SE (ETR:EVT) Shares Could Be 37% Below Their Intrinsic Value Estimate
May 13, 2023 | finanznachrichten.de
Evotec SE: Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023
May 12, 2023 | investing.com
Evotec SE ADR (EVO) Earnings Dates & Reports
May 10, 2023 | investing.com
Evotec SE ADR (EVO)
May 9, 2023 | finanznachrichten.de
Evotec SE: Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing
April 10, 2023 | finance.yahoo.com
Evotec SE Provides Update on Cyber Attack
February 10, 2023 | finanznachrichten.de
Evotec SE: Evotec Receives € 150 m Loan from European Investment Bank
January 31, 2023 | markets.businessinsider.com
EQS-NVR: Evotec SE: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
December 22, 2022 | ca.finance.yahoo.com
With 47% ownership, Evotec SE (ETR:EVT) has piqued the interest of institutional investors
December 17, 2022 | finanznachrichten.de
Evotec SE: Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb
September 21, 2022 | finanznachrichten.de
Evotec SE: Just - Evotec Biologics Awarded Contract from the U.S. Department of Defense Under Accelerated Antibodies Program
September 20, 2022 | markets.businessinsider.com
Evotec: US Unit Gets $49.9 Mln Antibodies Contract From U.S. Department Of Defense
September 17, 2022 | finanznachrichten.de
Evotec SE: Evotec Initiates Ground-Breaking for New Biologics Facility J.POD Toulouse, France
August 13, 2022 | seekingalpha.com
Evotec SE's (EVOTF) CEO Dr. Werner Lanthaler on Q2 2022 Results - Earnings Call Transcript
August 11, 2022 | nasdaq.com
Evotec Slips To Loss In Q3, Revenues Rise; Lifts FY22 Revenue View, Backs Adj. EBITDA Forecast
August 11, 2022 | markets.businessinsider.com
DGAP-News: Evotec SE reports results for the first half-year 2022 and provides corporate updates
See More Headlines
Receive EVTCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:EVTCY
CUSIP
N/A
CIK
1412558
Web
www.evotec.com
Phone
(494) 056-0810
Fax
49-40-5608-1222
Employees
3,572
Year Founded
1993

Profitability

EPS (Most Recent Fiscal Year)
$0.41
Trailing P/E Ratio
17.44
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$7.14 million
Net Margins
20.85%
Pretax Margin
23.90%
Return on Equity
16.02%
Return on Assets
7.81%

Debt

Debt-to-Equity Ratio
0.53
Current Ratio
2.57
Quick Ratio
2.50

Sales & Book Value

Annual Sales
$572.16 million
Price / Sales
4.13
Cash Flow
$0.07 per share
Price / Cash Flow
105.53
Book Value
$2.52 per share
Price / Book
2.84

Miscellaneous

Outstanding Shares
330,221,000
Free Float
N/A
Market Cap
$2.36 billion
Optionable
Not Optionable
Beta
0.98

Social Links

12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Werner Lanthaler
    Chief Executive Officer
  • Craig L. Johnstone
    Chief Operating Officer & Member-Management Board
  • Enno Spillner
    Chief Financial Officer
  • Cord E. Dohrmann
    Chief Scientific Officer
  • Volker Braun
    SVP, Head-Investor Relations & ESG

Key Competitors

View All Competitors

EVTCY Stock Analysis - Frequently Asked Questions

How have EVTCY shares performed in 2024?

Evotec's stock was trading at $11.73 at the beginning of the year. Since then, EVTCY stock has decreased by 39.0% and is now trading at $7.15.
View the best growth stocks for 2024 here.

When did Evotec's stock split?

Evotec shares split before market open on Wednesday, October 20th 2021. The 3-1 split was announced on Wednesday, October 20th 2021. The newly minted shares were distributed to shareholders after the closing bell on Wednesday, October 20th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

How do I buy shares of Evotec?

Shares of EVTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Evotec have any subsidiaries?
The following companies are subsidiares of Evotec: Aptuit, Bionamics GmbH, Cell Culture Service GmbH, Central Glass Germany, Central Glass Germany. GmbH, Compound Focus, Cyprotex, Develogen AG, Euprotec, Evotec (India) Private Ltd, GlaxoSmithKine's the Verona site, Just-Evotec Biologics, KINAXO Biotechnologies, Oxford Asymmetry International, RENOVIS, and Rigenerand Srl.
Read More
This page (OTCMKTS:EVTCY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
How Biden has already won 2024
Porter & Company
My biggest AI fear
Paradigm Press
Options trading has suddenly become more reliable.
Eagle Publishing